When Sirj Goswami was pursuing his PhD at UCSF in pharmacogenomics and quantitative pharmacology, clinicians from the University’s bone marrow transplant department approached him and his colleague Ron Keizer—who was also conducting pharmacology research at UCSF—for help. The clinicians wanted to develop a way to individualize the dosage of a highly toxic chemotherapy drug, Busulfan—used to treat children with leukemia as part of the child’s conditioning therapy in preparation for their bone marrow transplant. Pediatric patients are especially vulnerable to toxic therapies given that high exposure to chemotherapies during their developmental phase can impact their quality of life. Oncologists also knew that the current standard regimen overexposed the patients to toxic levels of chemotherapy and thus, tasked Keizer and Goswami with developing a novel method to optimize drug dosing. The duo created a sophisticated mathematical model to help those clinicians individualize drug dosing for every patient. They then turned the model into cloud-based software that UCSF’s oncology team could utilize at the point-of-care.
A year later, Goswami and Keizer left UCSF and recruited Ranvir Mangat, a drug development expert, to join them in founding InsightRX. The company’s vision was grand but clear: to help healthcare practitioners treat each patient individually by personalizing dosing regimens for complex medications, maximizing treatment efficacy and minimizing drug-related toxicity. “Our platform leverages artificial intelligence (AI) and quantitative pharmacology to help clinicians improve patient care,” says Goswami, CEO of InsightRX.
The company’s core product, InsightRX Nova, seamlessly integrates with hospitals’ electronic health records (EHR), enabling physicians and pharmacists to determine an individualized dosing regimen for a particular drug. For their customers, the InsightRX Nova platform is a goto tool in their armamentarium. “All of the information that is needed to individualize dosing by simulating the patient’s pharmacological and clinical response is pulled out of the EHR in seconds,” explains Goswami.“With a single click, a provider has access to all the relevant information they need to evaluate and individualize therapeutic regimens.”
While InsightRX started with one drug in bone marrow transplant, can now individualize therapy for over 40 different drugs across a variety of therapeutic areas including systemic antibiotics, solid organ transplant, and oncology. InsightRX Nova’s precision dosing information feeds directly into InsightRX Apollo, the company’s real-time predictive analytics dashboard. InsightRX Apollo allows hospital administrators, that allows hospital administrators to monitor clinical outcomes, assess treatment guidelines, and comply with Joint Commission standards.
We envision InsightRX being the leader in leveraging artificial intelligence to develop digital therapeutics which augment medicine at the point of care
InsightRX is empowering medical centers to determine the right quantity of medication for patients. One of InsightRX’s clients saved over a million dollars during a five-month pilot period for a single antibiotic. The client used InsightRX’s platform to reduce the incidence of vancomycinassociated acute kidney injury—a nephrotoxic event that occurs when a patient is exposed to toxic levels of vancomycin. InsightRX prospectively compared the use of InsightRX to the hospital’s “baseline” data collected prior to the start of the study. “We compared the post-analysis results with the pre-analysis outcomes and noticed that we had reduced the incidence of acute kidney injury significantly, after which the client implemented our platform across their entire hospital system,” says Goswami.
Today, InsightRX has amassed a large customer base in the U.S. and Europe and plans to expand across the globe. The company also has partnerships with biotechnology and pharma companies to improve treatment administration of complex drugs. Their portfolio of solutions are currently being utilized in clinical studies funded by the National Institute of Health (NIH). “We are also developing digital therapeutics to augment medicine at the point-of-care and envision being a leader in leveraging AI to improve clinical outcomes across several therapeutic areas. We want to accelerate and support the healthcare industry’s adoption of evidencebased care,” concludes Goswami.